Next-Generation Targeted Delivery Systems with Enhanced Shiga Toxin Effector Polypeptides

The inventive concept envisions a next-generation targeted delivery system leveraging enhanced Shiga toxin effector polypeptides with improved binding affinity, cytotoxicity, and selectivity, thereby revolutionizing the treatment of diseases and disorders.

The original patent disclosed cell-targeting molecules comprising Shiga toxin effector polypeptides for site-specific conjugation. However, these molecules may have limitations in terms of binding affinity, cytotoxicity, and selectivity. The new inventive concept addresses these limitations by introducing engineered Shiga toxin effector polypeptides with enhanced properties, enabling more effective and targeted therapies.

The inventive concept comprises a system for targeted delivery of Shiga toxin effector polypeptides, featuring a cell-targeting molecule with an engineered Shiga toxin effector polypeptide having at least one amino acid substitution conferring enhanced binding affinity to a target biomolecule. The cell-targeting molecule is encapsulated in a nano-carrier designed to release the molecule in response to a specific physiological signal. Additionally, the inventive concept encompasses methods for treating diseases or disorders using these cell-targeting molecules, as well as compositions and kits for preparing such molecules.

The new inventive concept introduces the use of engineered Shiga toxin effector polypeptides with enhanced binding affinity, cytotoxicity, and selectivity, which is not anticipated by the original patent. The combination of these polypeptides with nano-carriers and payload molecules represents a non-obvious advancement in the field of targeted delivery systems.

Alternative embodiments of the inventive concept may include the use of different nano-carrier materials, payload molecules, or targeting moieties. Variations may also include the application of the inventive concept to different disease or disorder areas, such as cancer, autoimmune diseases, or infectious diseases.

The inventive concept has significant commercial potential in the development of targeted therapies for various diseases and disorders. The market for such therapies is expected to grow substantially, driven by the increasing need for more effective and selective treatments. The inventive concept is poised to capture a significant share of this market, offering a competitive advantage to companies and researchers developing targeted delivery systems.